Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BY-NC-ND 4.0Mediastinum

AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours

12 more authors
  1. 1Guy’s and St. Thomas’ NHS Foundation Trust, London, UK
  2. 2King’s College London, London, UK

Abstract

Background: Thymic epithelial tumours (TETs) are rare malignancies for which surgical resection is the primary curative treatment. Chemotherapy may be given neoadjuvantly to facilitate resection of locally advanced disease, or adjuvantly to reduce recurrence risk, but the impact of these strategies is not well defined.

Methods: We retrospectively reviewed demographic, disease, treatment and outcome data for all patients with histologically confirmed TETs managed at our centre (April 2011–November 2022). Disease was staged per tumor-node-metastasis (TNM) 8th edition. Survival outcomes were analysed using Kaplan-Meier and log-rank tests.

Results: 206 patients were identified (52% male; median age 63 years); 189 (92%) had thymoma, 16 (8%) thymic carcinoma and 1 thymic atypical carcinoid. Thirty-six patients (17.5%) received neoadjuvant chemotherapy (NACT), given only for stage II–IV disease (30 thymoma, 6 thymic carcinoma), and were compared with 14 stage II–IV patients managed without NACT (10 thymoma, 3 thymic carcinoma and 1 atypical carcinoid). NACT patients had more advanced disease than patients without NACT (Stage III/IV 94.4% vs. 57.1%, P=0.003). All NACT patients proceeded to surgery; R0 resection was achieved in 58.3% of patients (Stage II 100%, Stage III 64.7%, Stage IV 47.1%), and pathologic complete response (pCR) in 11.1% (all thymoma). Recurrence was numerically higher with NACT than without (38.9% vs. 14.3%, P=0.18), 5-year event free survival (EFS) was 46.5% vs. 60.9% (P=0.79), and 5-year overall survival (OS) was 80.9% vs. 66.6% (P=0.47). Thirteen patients (6.3% of total; 11 thymoma, 2 thymic carcinoma) received adjuvant chemotherapy, more often for higher-stage disease (P<0.001) and more aggressive subtypes (P=0.001). Recurrence was 15.4% with adjuvant chemotherapy versus 10.4% without (P=0.63), five-year EFS was 83.3% versus 75.0% (P=0.41), and 5-year OS was 91.7% versus 85.0% (P=0.40).

Conclusions: NACT was used predominantly for more advanced disease, achieving pCR in 11% of patients. Adjuvant chemotherapy was similarly reserved for more advanced disease and aggressive histology. Given this confounding by indication, and the small and imbalanced group sizes, no firm conclusions on treatment benefit can be drawn. As the benefit of neoadjuvant and adjuvant chemotherapy in TETs remains unclear, larger studies, such as national registry collaborations, are needed to provide further insight.

Related

  1. Perioperative Safety, Surgical Morbidity, and Survival Outcomes of Neoadjuvant Chemotherapy (NACT-IDS) versus Primary Debulking Surgery (PDS) in Elderly Patients with Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis
    A. Rafiee, M. A. Boroumand, S. Taghipour Zahir
    medRxivPreprintCC BYFull textObstetrics, gynaecology & paediatricsmedRxiv
  2. Patient-reported Symptom Resolution After Neoadjuvant Versus Adjuvant Chemotherapy for Early Breast Cancer: A Prospective Observational Cohort Study
    TAKAAKI FUJII, KEI ICHIBA, MAYU AOKI +4
    In VivoPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  3. Association between neoadjuvant and adjuvant chemotherapy and severity of breast cancer-related lymphedema following axillary lymph node dissection
    Ramesh Omranipour, Mohammadamin Bayat, Sadaf Alipour +5
    BMC CancerPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  4. Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study.
    T Gaillard, P Cottu, O Tredan +12
    ESMO real world data and digital oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Barriers and facilitators to self-management among patients with breast cancer receiving neoadjuvant chemotherapy: A qualitative study informed by the integrated theory of health behavior change
    Yanling Jiang, Chaixiu Li, Yinhuan Wang +3
    Asia-Pacific Journal of Oncology NursingPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
BibTeX
@article{konstantinidou2026ab036,
  title = {{AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours}},
  author = {Eirini Konstantinidou and Eleni Josephides and Diluxshan Sritharan and Mariam Jallow and Shahreen Ahmad and Daniel Smith and Michael Skwarski and Daniel Hughes and Sharmistha Ghosh and Spyridon Gennatas and Alexandros Georgiou and Mieke Van Hemelrijck and Nikolaos Syrigos and Marrika Colvin and Ellie McDowall and Karen Harrison-Phipps and Leanne Ashrafian and Tom Routledge and Carol Tan and Akshay Patel and George Santis and Thomas Young and Andrea Bille and Eleni Karapanagiotou},
  journal = {Mediastinum},
  year = {2026},
  month = oct,
  doi = {10.21037/med-26-ab036},
  url = {https://doi.org/10.21037/med-26-ab036},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours
AU  - Eirini Konstantinidou
AU  - Eleni Josephides
AU  - Diluxshan Sritharan
AU  - Mariam Jallow
AU  - Shahreen Ahmad
AU  - Daniel Smith
AU  - Michael Skwarski
AU  - Daniel Hughes
AU  - Sharmistha Ghosh
AU  - Spyridon Gennatas
AU  - Alexandros Georgiou
AU  - Mieke Van Hemelrijck
AU  - Nikolaos Syrigos
AU  - Marrika Colvin
AU  - Ellie McDowall
AU  - Karen Harrison-Phipps
AU  - Leanne Ashrafian
AU  - Tom Routledge
AU  - Carol Tan
AU  - Akshay Patel
AU  - George Santis
AU  - Thomas Young
AU  - Andrea Bille
AU  - Eleni Karapanagiotou
PY  - 2026
DA  - 2026/10/30
JO  - Mediastinum
DO  - 10.21037/med-26-ab036
UR  - https://doi.org/10.21037/med-26-ab036
AB  - Background: Thymic epithelial tumours (TETs) are rare malignancies for which surgical resection is the primary curative treatment. Chemotherapy may be given neoadjuvantly to facilitate resection of locally advanced disease, or adjuvantly to reduce recurrence risk, but the impact of these strategies is not well defined.  Methods: We retrospectively reviewed demographic, disease, treatment and outcome data for all patients with histologically confirmed TETs managed at our centre (April 2011–November 2022). Disease was staged per tumor-node-metastasis (TNM) 8th edition. Survival outcomes were analysed using Kaplan-Meier and log-rank tests.  Results: 206 patients were identified (52% male; median age 63 years); 189 (92%) had thymoma, 16 (8%) thymic carcinoma and 1 thymic atypical carcinoid. Thirty-six patients (17.5%) received neoadjuvant chemotherapy (NACT), given only for stage II–IV disease (30 thymoma, 6 thymic carcinoma), and were compared with 14 stage II–IV patients managed without NACT (10 thymoma, 3 thymic carcinoma and 1 atypical carcinoid). NACT patients had more advanced disease than patients without NACT (Stage III/IV 94.4% vs. 57.1%, P=0.003). All NACT patients proceeded to surgery; R0 resection was achieved in 58.3% of patients (Stage II 100%, Stage III 64.7%, Stage IV 47.1%), and pathologic complete response (pCR) in 11.1% (all thymoma). Recurrence was numerically higher with NACT than without (38.9% vs. 14.3%, P=0.18), 5-year event free survival (EFS) was 46.5% vs. 60.9% (P=0.79), and 5-year overall survival (OS) was 80.9% vs. 66.6% (P=0.47). Thirteen patients (6.3% of total; 11 thymoma, 2 thymic carcinoma) received adjuvant chemotherapy, more often for higher-stage disease (P<0.001) and more aggressive subtypes (P=0.001). Recurrence was 15.4% with adjuvant chemotherapy versus 10.4% without (P=0.63), five-year EFS was 83.3% versus 75.0% (P=0.41), and 5-year OS was 91.7% versus 85.0% (P=0.40).  Conclusions: NACT was used predominantly for more advanced disease, achieving pCR in 11% of patients. Adjuvant chemotherapy was similarly reserved for more advanced disease and aggressive histology. Given this confounding by indication, and the small and imbalanced group sizes, no firm conclusions on treatment benefit can be drawn. As the benefit of neoadjuvant and adjuvant chemotherapy in TETs remains unclear, larger studies, such as national registry collaborations, are needed to provide further insight.
SN  - 2522-6711
ER  -